- Home
- TMHC vs BLTE Comparison
TMHC vs BLTE Comparison
Compare TMHC & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TMHC | BLTE |
|---|---|---|
| Founded | 1936 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.5B |
| IPO Year | 2012 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TMHC | BLTE |
|---|---|---|
| Price | $58.02 | $170.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $78.75 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 1.0M | 135.7K |
| Earning Date | 04-22-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.77 | N/A |
| Revenue | ★ $4,762,059,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.86 | $492.11 |
| P/E Ratio | $7.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $51.90 | $49.00 |
| 52 Week High | $72.27 | $200.00 |
Technical Indicators
Market Signals| Indicator | TMHC | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 39.91 | 55.37 |
| Support Level | $57.19 | $167.80 |
| Resistance Level | $65.18 | $174.78 |
| Average True Range (ATR) | 1.57 | 8.24 |
| MACD | 0.06 | 1.31 |
| Stochastic Oscillator | 30.96 | 78.61 |
Price Performance
Historical ComparisonAbout TMHC Taylor Morrison Home Corporation
Taylor Morrison Home Corp is an American residential construction company engaged in residential homebuilding and the development of lifestyle communities. It designs, builds, and sells single and multi-family detached and attached homes in traditionally high growth markets for entry level, move-up, and resort lifestyle buyers. The company has four reportable segments: East, Central, West, and Financial Services. The majority of the company's revenue is derived from its West Segment.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.